MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2020

September 12-16, 2020. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z
  • Tardive Dystonia Successfully treated with DBS

    M. Ferreira Cordellini, D. Benzecry Almeida (Curitiba, Brazil)

  • Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease

    Y. Sidorova, A. Mahato, M. Saarma (Helsinki, Finland)

  • Task based profiles of language impairment in Parkinson’s Disease

    A. Lowit, M. Roheger, E. Kalbe, T. Thies, J. Steffen, M. Barbe (Glasgow, United Kingdom)

  • Tau Neuropathology Associates with In Vivo Patterns of Neurodegeneration in Lewy Body Disorders

    N. Spotorno, D. Coughlin, L. Shaw, A. Chen-Plotkin, D. Weintraub, E. Lee, J. Trojanowski, C. McMillan, D. Irwin, M. Grossman (Philadelphia, PA, USA)

  • TAU pathology contributes to specific patterns of structural brain damage and neuropsychological heterogeneity in Huntington’s disease

    S. Martinez-Horta, J. Perez-Perez, R. Perez-Gonzalez, A. Horta-Barba, F. Sampedro, E. Rivas-Asensio, T. Xucla, M. Guasch, A. Campolongo, C. Izquierdo-Barrionuevo, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

  • Technology-based therapy response and prognostic biomarkers in Parkinson’s disease: results from a prospective evaluation of a de novo PD patients’ cohort

    G. Di Lazzaro, M. Ricci, T. Schirinzi, S. Scalise, G. Saggio, N.B Mercuri, A. Pisani (Rome, Italy)

  • Temporal characterization of motor, gastrointestinal, and behavioral symptoms in a SNCA A53T transgenic mouse model of Parkinson’s disease

    N. Radisavljevic, M. Cirstea, K. Bauer, B. Finlay (Vancouver, BC, Canada)

  • Temporal properties of resting-state functional MRI are associated with ON/OFF levodopa MDS-UPDRS III scores in patients with Parkinson’s disease

    M. Morrison, A. Lee, S. Wang, A. Martin, I. Bledsoe, J. Ostrem, P. Larson, P. Starr, D. Wang (San Francisco, CA, USA)

  • Temporhythmal Correction: The New Way of Therapy and Diagnostic Secondary Vascular Parkinsonism

    D.T Akramova (Tashkent, Uzbekistan)

  • Test-Retest Reliability of Sensor-Based Telemonitoring of Parkinsonian Gait at Home

    G. Rigas, N. Kostikis, N. Tachos, K. Tsamis, D. Kakalou, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)

  • TET2-mediated Cdkn2A DNA hydroxymethylation in dopaminergic neuronal injury of Parkinson’s disease

    Y.C Wu, TT. Wu, X. Li, T. Liu (Shanghai, China)

  • Thalamic Deep Brain Stimulation for Acquired Dystonia in Children and Young Adults: A Phase I Clinical Trial

    M. San Luciano, A. Viehoever, I. Bledsoe, K. Dodenhoff, M. Gittings, A. Viser, C. Racine-Belkoura, C. Pereira, S. Wang, P. Starr, J. Ostrem (San Francisco, CA, USA)

  • Thalamic deep brain stimulation improves tremor and spatio-temporal characteristics of gait in medically refractory orthostatic tremor

    A. Giritharan, M. Mancini, S. Stuart, R. Morris, S. Anderson, J. Wilhelm, J. Nutt (Portland, OR, USA)

  • Thalamic nuclei volumes and intrinsic thalamic network in motor subtype in Parkinson’s disease

    J. Park, H.T Kim (Busan, Republic of Korea)

  • The ‘A’ in the A/T/N Alzheimer’s Disease Biomarker Classification Predicts Cognitive Outcomes in Parkinson’s Disease

    N. Han, D. Weintraub, L. Shaw, J. Trojanowski, A. Chen-Plotkin, T. Tropea (Philadelphia, PA, USA)

  • The Accreditation and Certification of the Movement Disorders Subspecialty: A Five-Year Follow-Up Study

    S. O'Shea, L. Gutmann, L. Faulkner (Boston, MA, USA)

  • The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: A pilot study

    H.C Chang, Y.C Tsai, C.S Lu (Taoyuan City, Taiwan)

  • The ADNPC-RS: a risk score that identifies Lewy body disease individuals at risk for developing concomitant Alzheimer’s pathology

    D. Dai, T. Tropea, J. Robinson, E. Suh, H. Hurtig, D. Weintraub, V. Van Deerlin, E. Lee, J. Trojanowski, A. Chen-Plotkin (Philadelphia, PA, USA)

  • The association between thinning of cerebral cortex and age of onset in Parkinson’s disease

    K. Seo, R. Yokohama, Y. Ito, Y. Nakazato, I. Matunari, H. Matuda, T. Yamamoto (Saitama, Japan)

  • The Association of Taichi to Delayed Progression of Parkinson’s Disease

    P. Huang, G. Li, Y.C He, S.D Chen (Shanghai, China)

  • The Benchmark Clinic: A Comprehensive Care Model for People with Parkinson’s Disease

    S. Mantri, K. Mitchell, A. Allen, N. Bukhari-Parlakturk, N. Calakos, J. Cooney, J. Montgomery, M. Ivancic, A. Kosem, E. Nixon, M. Nye, B. Scott, K. Struble, M. Werz (Durham, NC, USA)

  • The Care Partner Perspective: Most Challenging Parkinson’s Symptoms

    A. Wallis, D. Perret (Miami, FL, USA)

  • The clinical features of non-motor symptoms in Parkinson’s Disease with Rapid Eye Movement Sleep Behavior Disorder(RBD)

    Y. Wang, Z.H Liang (Dalian, China)

  • The clinical features, treatments and genetic characteristics in Chinese children with dopa-responsive dystonia

    L. Dai, C. Ding, F. Fang (Beijing, China)

  • The Clinical Heterogeneity of Orthostatic Hypotension in PD Patients

    P.Z Li, LL. Peng, J.L Wang, Y.M Liu (Jinan, China)

  • The clinical significance of the swallow tail sign in distinguishing Parkinson’s disease patients from healthy individuals

    J. Prasuhn, A. Neumann, R. Strautz, S. Dreischmeier, F. Lemmer, H. Hanßen, M. Heldmann, N. Brüggemann (Lübeck, Germany)

  • The clinical spectrum of movement disorders associated with neuronal antibodies

    V. Karthikeayan, A. Randall, E. Jackson, S. Huda, M. Bonello (Liverpool, United Kingdom)

  • The clinical utility of programming method for multi-contact electrodes of deep brain stimulation in Parkinson’s disease

    T. Nagao, T. Nagao, M. Nemoto, N. Sugo (Sakura city, Japan)

  • The Cognitive Training In Parkinson Study (COGTIPS), a randomized controlled trial

    T. van Balkom, H. Berendse, Y. v.d. Werf, J. Twisk, R. Hagen, T. Berk, O. v.d. Heuvel, C. Vriend (Amsterdam, Netherlands)

  • The cold hand sign in multiple system atrophy: prevalence, associated factors and impact on survival

    B. Cao, L.Y Zhang, QQ. Wei, R.W Ou, H.F Shang (Chengdu, China)

  • The development and application of an adjunct genetic counseling pre-test assessment and video intervention for Parkinson’s disease (PD)

    S. Elango, V. Katsnelson, D. Raymond, S. Rodriguez, T. Lin, N. Urval, R. Ortega, S. Bressman, R. Saunders-Pullman (New York, NY, USA)

  • The diagnostic value of smartphone-based instrumented Timed Up & Go test in different movement disorders

    G. Yahalom, S. Israeli-Korn, T. Fay-Karmon, V. Livneh, K. Tchelet, Z. Yekutieli, A. Stark-Inbar, S. Hassin-Baer, H. Yahalom, M. Linder (Jerusalem, Israel)

  • The distinct EEG signature of celiac disease-related cortical myoclonus

    E. Swinkin, K. Lizarraga, M. Algarni, L. Dominguez, J. Baarbe, J. Saravanamuttu, R. Chen, E. Slow, A. Lang, R. Wennberg (Toronto, ON, Canada)

  • The dual cognitive syndrome in Parkinson’s disease: volumetric, morphological and tractometric features

    Q. Devignes, R. Viard, R. Lopes, N. Betrouni, G. Kuchcinski, G. Carey, L. Defebvre, A. Leentjens, K. Dujardin (Lille, France)

  • The dysfunctional autonomic function and “dysfunctional” fatigue in drug naïve Parkinson’s disease

    J.H Ahn, M. Kim, J.K Mun, J.S Kim, J. Song, J. Youn, J.S Kim, J.W Cho (Seoul, Republic of Korea)

  • The Dystonia Coalition Natural History Project: An Available Research Resource

    S. Norris, H. Jinnah, L. Wright, G. Kilic-Berkmen, J. Hieshetter, D. Peterson, S. Pirio-Richardson, J. Perlmutter (St. Louis, MO, USA)

  • The effect of botulinum toxin A on pain associated with cervical dystonia (CD) in routine clinical practice

    R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

  • The effect of comorbid NPH on the clinical feature and progression of Parkinson’s disease

    A. Hattori, T. Tsunemi, Y. Ishiguro, N. Hattori (Tokyo, Japan)

  • The effect of Deep Brain Stimulation in patients with Parkinson’s Disease on the Brain Cognitive Functions

    A. Ivashynka, A. Cucovici (Novara, Italy)

  • The effect of exercise on pain in Parkinson’s disease: A protocol for a systematic review

    V. Nguy, L. Hassett, C. Canning, J. Elliott, N. Allen (Sydney, Australia)

  • The effect of levodopa and cognitive-motor dual interference on gait parameters in PD FOG

    J. Longhurst, J. Rider, B. Bluett, M. Landers (Las Vegas, NV, USA)

  • The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease

    B.G Koçer, E.A Özturk, SS. Çomoğlu (Ankara, Turkey)

  • The effect of severity of Parkinson’s disease on chronic headache

    J.Y Ahn, H.T Kim (Seoul, Republic of Korea)

  • The Efficacy of Teleconsultation for Management of Movement Disorders in Thailand

    W. Phuenpathom, P. Jagota, R. Bhidayasiri (Bangkok, Thailand)

  • The efficacy of traditional Mikkyo Buddhism meditation in stress management of Parkinson’s syndrome patients

    S. Murahashi, Y. Takeuchi, Y. Hara (Yatsushiro, Japan)

  • The exosomal a-syn filaments can be a novel biomarker of Parkinson’s disease

    Y. Ishiguro, T. Tsunemi, A. Yoroisaka, N. Hattori (Tokyo, Japan)

  • The feasibility of cognitive telerehabilitation in patients with Parkinson´s disease: The pilot data

    V. Plzáková (Prague, Czech Republic)

  • The feasibility of detailed phenotyping of muscle mitochondrial respiratory chain function and content in Parkinson’s disease

    A. Yarnall, A. Granic, S. Waite, K. Hollingsworth, C. Warren, A. Vincent, G. Gorman, D. Turnbull, R. Taylor, R. Dodds, A. Sayer (Newcastle upon Tyne, United Kingdom)

  • The Feasibility of Using of the Non-Medication in the Treatment of Post-Stroke Vascular Parkinsonism

    O. Tondiy, O. Zavalna (Kharkiv, Ukraine)

  • The First-Ever CNV Analysis in Latin American Parkinson’s Disease Patients

    E.I Sarihan, E. Pérez-Palma, L.M Niestroj, D. Loesch, M. Seyfi, M. Inca-Martinez, A. Horimoto, M. Cornejo-Olivas, L. Torres, P. Mazzetti, C. Cosentino, E. Dieguez, V. Raggio, A. Lescano, V. Tumas, V. Borges, H.B Ferraz, C. Rieder, A. Schumacher-Schuh, B.L Santos-Lobato, C. Velez-Pardo, M. Jimenez-Del-Rio, F. Lopera, P. Chana-Cuevas, W. Fernandez, G. Arboleda, H. Arboleda, C.E Arboleda-Bustos, D. Yearout, C.P Zabetian, T. Thornton, T.D O’Connor, D. Lal, I.F Mata (Cleveland, OH, USA)

  • The Fragile X Mental Retardation Protein is lost prior to the appearance of Lewy pathology in Parkinson’s disease

    T. Koeglsperger, Y. Tan, C. Sgobio, T. Arzberger, F. Machleid, Q. Tang, E. Findeiss, J. Tost, T. Chakroun, P. Gao, M. Höllerhage, K. Bötzel, J. Herms, G. Höglinger (Evry Cedex, France)

  • The Future of Hospitalization for People with Parkinson’s Disease

    A. Wallis, D. Perret (Miami, FL, USA)

  • The genetic study of autosomal dominant spinocerebellar ataxia in Kazakhstan

    R. Kaiyrzhanov, N. Zharkinbekova, A. Aitkulova, J. Jarmukhanov, V. Akhmetzhanov, A. Taskynbayeva, C. Shashkin (Shymkent, Kazakhstan)

  • The genetic study of hereditary chorea in Kazakhstan

    R. Kaiyrzhanov, N. Zharkinbekova, A. Aitkulova, V. Akhmetzhanov, Z. Jarmukhanov, H. Houlden (London, United Kingdom)

  • The Gut Dysmotility Questionnaire (GDQ) for Parkinson’s disease: current development

    V. Räder, K.R Chaudhuri, L. Batzu, V. Leta, H. Reichmann, B. Falkenburger, L. Klingelhoefer (Dresden, Germany)

  • The Impact of Antipsychotic Dose Reduction Within a Medicare Population

    R. Ayyagari, F. Mu, A. Lax, B. Carroll (Boston, MA, USA)

  • The impact of anxiety on social functioning in Parkinson’s disease

    K. Perepezko, J. Hinkle, K. Mills, G. Pontone (Baltimore, MD, USA)

  • The impact of motor and non-motor symptoms on walking capacity in people with Parkinson’ disease

    H. Khalil, R. Rayhan, A. Al-Sharman, A. Aburub, K. El-Salem (Irbid, Jordan)

  • The Impact of the Sensory Trick on Gating Multimodal Afferents in Cervical Dystonia

    F. Brugger, J. Michelis, J. Walch, G. Kägi (St. Gallen, Switzerland)

  • The incidence, predictors, and outcomes of delirium in Parkinson’s disease and atypical parkinsonism

    S. Green, A. McCleary, I. Sleeman, J. Maple-Grødem, C. Counsell, A. Macleod (Aberdeen, United Kingdom)

  • The Indian Experience of Continuous Dopaminergic therapy with Apomorphine in Parkinson’s Disease

    D. Hoskere Sreenivasa, R. Jayachandran, R. Seetharam, R. Iyer, P. Kukkle (Bangalore, India)

  • The Influence of 3-Phenoxybenzoic Acid in Dopaminergic Degeneration

    F. Wan (Wuhan, China)

  • The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease

    B. Radojević, N. Dragašević-Mišković, A. Marjanović, A. Milovanović, M. Svetel, I. Petrović, M. Savić, I. Jančić, V. Kostić (Belgrade, Serbia)

  • The interaction of Parkin and TAF15 for the Drosophila in which neuronal defect was induced

    E.J Choi, D.G Lee, CC. Cui, K.Y Kim (Ulsan, Republic of Korea)

  • The interplay between asymmetric dopaminergic degeneration, brain structural changes and cognition in de-novo PD: The PPMI dataset

    E. Fiorenzato, A. Antonini, W. Weis, P. Bisiacchi, C. Semenza, A. Vallesi, R. Biundo (Venice, Italy)

  • The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses

    H. Frequin, J. Schouten, R. de Bie, L. LEAP-study group (Amsterdam, Netherlands)

  • The Many Faces of Bradykinesia in Parkinson’s Disease : The Quantitative Analysis from A Keyboard Typing Test

    P. Panyakaew, K. Duangjino, T. Ploensin, K. Piromsopa, R. Bhidayasiri (Bangkok, Thailand)

  • The non-declaration of musculoskeletal pain in Parkinson’s disease in patient-related outcome measures –The King’s experience

    K. Rukavina, M. Krbot Skoric, C. Borley, L. Batzu, A. Rizos, D. van Wamelen, K. Ray Chaudhuri (London, United Kingdom)

  • The pathophysiology of dystonic tremors and comparison with essential tremor

    P. Panyakaew, H.J Cho, S.W Lee, M. Hallett (Bangkok, Thailand)

  • The Personalized Parkinson Project – data quality enhancing strategies

    B. Bloem, L. Evers, T. vande Zande, R. Kapur, M. Meinders, W. Marks, Jr (Nijmegen, Netherlands)

  • The Phenotypical Presentation of SCA8 in Taiwan

    Y.C Liaw, H.L Chiang (Taipei City, Taiwan)

  • The Presence of Efferent Brain-Gut Neuropathy Correlates with Severe Constipation in Parkinson’s disease

    A. Sharma, Y. Yan, T. Karunaratne, A. Eubanks, J. Kurek, J. Morgan, S. Rao (Augusta, GA, USA)

  • The Progressive Supranuclear Palsy Clinical Deficits Scale

    G. Respondek, I. Piot, K. Schweyer, M. Stamelou, P. Sckopke, T. Schenk, C. Goetz, T. Stebbins, G. Höglinger (Hannover, Germany)

  • The relationship between MIBG myocardial scintigraphy and clinical factors in multiple system atrophy

    R. Yokoyama, R. Okuda, K. Seo, K. ota, H. Kawasaki, K. Kazushi, Y. Nakazato, I. MatunariI, N. Tamura, T. Yamamoto (Saitama, Japan)

  • The Relationship Between Modified Four Square Step Test (mFSST) and Outcome Measures Related to Fall Risk and Quality of Life in Individuals with Parkinson’s Disease

    A. Boddy, K. Mitchell, W. Brewer, J. Ellison (St. Augustine, FL, USA)

  • The relationship between neuromelanin-sensitive MRI, [123I] meta-iodobenzylguanidine scintigraphy and cognition, in patients with Parkinson’s disease

    T. Utsunomiya, K. Matsuura, Y. Ii, A. shindo, m. Umino, M. Maeda, H. Tomimoto (Tsu Mie, Japan)

  • The relationship between REM sleep behavior disorder and cognitive impairment in drug-naïve Parkinson’s disease

    A. Karukote, S. Thakolwiboon, P. Julayanont (Lubbock, TX, USA)

  • The relationship between serum uric acid and depression in patients with essential tremor

    Z. Muruzheva, I. Ivleva, M. Karpenko (Saint-Petersburg, Russian Federation)

  • The role of attention networks in walking in Parkinson’s disease

    R. Drake, G. Eskes (Halifax, NS, Canada)

  • The role of dementia in Parkinson’s disease

    A. Aralbayeva, A. Kondybaeva, S. Kamenova, K. Kuzhibaeva (Almaty, Kazakhstan)

  • The Role of Directional Configuration for Essential Tremor: A Single Center Experience

    V. Veerappan, A. Hiller (Portland, OR, USA)

  • The role of dopamine mis-metabolism in preclinical Parkinson’s disease olfactory deficits

    L. Beauchamp, L. Vella, A. Bush, K. Barnham (Melbourne, Australia)

  • The role of low contrast visual acuity in cognitive performance in Lewy body diseases

    R. Del Pino, M. Acera, A. Murueta-Goyena, O. Lucas-Jiménez, N. Ojeda, N. Ibarretxe-Bilbao, J. Peña, P. Reyero, J. Cortés, B. Tijero, M. Galdós, J.C Gómez-Esteban, I. Gabilondo (Barakaldo, Spain)

  • The role of peripheral T- and B-lymphocytes in LRRK2-mediated Parkinson’s disease

    E. Kozina, M. Byrne, L. Oakley, R. Smeyne (Philadelphia, PA, USA)

  • The role of polymorphic allelic variants of the VEGFα and TGFβ gene in the development of cerebrovascular disorders in patients with metabolic syndrome

    S.h Shokhimardonov, S.h Xudjanov, F. Shermuhammedova, S.h Kuzieva (Tashkent, Uzbekistan)

  • The role of the disorders in interaction between visual and oculomotor systems and their MRI correlation in patients with camtocormia in Parkinson’s disease

    O. Alenikova, S. Likhachev (Minsk, Belarus)

  • The roles of Huntingtin Associated Protein 40 in Huntingtin functions and Huntington’s disease pathogenesis

    S. Xu, G. Li, X. Ye, L. Ye, Z. Xu, E. Furr Stimming, S. Zhang (Houston, TX, USA)

  • The ROPAD (Rostock International Parkinson’s Disease Study) study: Towards defining the genetic epidemiology of the disease

    V. Skrahina, H. Gaber, T. Förster, T. Usnich, N. Schell, P. Bauer, X. Bogdanovic, E. Vollstedt, N. Brüggemann, I. Csoti, M. Kasten, N. Koleva-Alazeh, C. Beetz, C. Klein, A. Rolfs (Rostock, Germany)

  • The severity and distribution of tau pathology distinguish corticobasal degeneration and progressive supranuclear palsy

    S. Koga, N. Ghayal, S. Roemer, D. Dickson (Jacksonville, FL, USA)

  • The short- and long-term outcomes of STN DBS in PD patients with or without RBD

    S.M Park, R. Kim, J.H Shin, H.J Kim, B.S Jeon (Seoul, Republic of Korea)

  • The sooner, the better: early diagnosis and treatment in functional neurological disorders

    P. Parra-Díaz, J.L Chico García, E. Natera Villalba, V. Nedkova Hristova, F. Rodríguez Jorge, Á. Beltrán Corbellini, J.C Martínez Castrillo, J. Masjuan, A. Alonso Cánovas, I. Pareés Moreno (Madrid, Spain)

  • The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease: a pilot study

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, A. Baitimerov, G. Tayupova, R. Magzhanov (Ufa, Russian Federation)

  • The Subthalamic Fasciculus and Connectivity Profiling of Stimulation-induced Dyskinesia following Pallidal DBS in Parkinson’s Disease

    T. Tsuboi, A. Elkouzi, W. Deeb, A. Ramirez-Zamora, L. Almeida, P. Zeilman, R. Eisinger, K. Foote, L. Okromelidze, S. Grewal, M. Okun, E. Middlebrooks (Gainesville, FL, USA)

  • The Unique Voiceprint Changed In Parkinson’s Disease

    F. XU (CHENGDU, China)

  • The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease

    T. Payne, M. Appleby, E. Buckley, C. Mazza, T. Foltynie, O. Bandmann (Sheffield, United Kingdom)

  • The use of Virtual Reality to Assess the Quality of Life in Patients with Spinocerebellar Ataxia

    B. Zeigelboim, B. Cavalcante-Leao, J.M Malisky, G.S Santos, M.S Severiani, H.T Teive (Curitiba, Brazil)

  • The usefulness of a dual-phase 18-F-FP-CIT PET in a case of Alzheimer’s disease with slow movement

    WW. Lee (Seoul, Republic of Korea)

  • The utility of single dose levodopa challenges in the management of Parkinson’s disease

    D. Tsui, D. Galea, N. Mahant, S. Kim, S. Babu, V. Fung (Sydney, Australia)

  • The variants of autophagy genes of early-onset Parkinson’s disease

    H. Chang, E. Oh, J. Youn, J. Park, S. Kim, W. Jang (Daejeon, Republic of Korea)

  • Therapeutic Benefits of Music for Three Types of Neurological Disorders: an fNIRS Study Protocol for Controlled Trial in Dalian, China, Part 1-Parkinson’s Disease

    LL. Pu, Z.H Liang, W.C Tang, F.Y Cong, B.W Zhang, N.K Qureshi, J. Ly, T. Li (Dalian, China)

  • Therapeutic effect of OnabotulinumtoxinA in bilateral hemifacial spasm, trigeminal neuralgia and chronic migraine in El Salvador

    J. Lopez-Castellanos, J. Lopez Contreras (Little Rock, AR, USA)

  • Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes

    S. Hussain, A. Singh, H. Baxi, B. Taylor, J. Burgess, B. Antony (Delhi, India)

  • Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease

    C. Christine, R. Richardson, A. Van Laar, M. Thompson, K. Herbert, C. Li, G. Liang, E. Fine, P. Larson (San Francisco, CA, USA)

  • Time matters in brain health: how can health systems respond to the growing demand for genetic testing?

    A. Noyce, G. Giovannoni, P. Scheltens, D. Berg, L. Brown, K. Dierickx, G. Frisoni, J. Georges, J. Hardy, K. Heilbron (London, United Kingdom)

  • Time Series Analysis Applied to EEG Shows Increased Global Connectivity During Motor Activation in PD Patients Compared to Controls

    D. Herráez, A. Maitín, R. Perezzan, M.D Castillo, I.J Serrano, A. Arroyo, J. Andreo, J.P Romero (Madrid, Spain)

  • Topographical subtypes of multiple system atrophy: MRI and PET studies

    C. Lee, K. Park, N. Choi, S. Kim, J. Ko, D. Doudet (Seoul, Republic of Korea)

  • Toward the digitization of the International Parkinson and Movement Disorder Society rating scales

    M. Monje, R. Fuller, E. Cubo, T. Mestre, A. Tan, J. Stout, S. Ali, L. Chahine, K. Dujardin, C. Fitzer-Attas, J. Youn, B. Bloem, F. Horak, A. Merola, R. Reilmann, S. Paul, R. Dorsey, W. Maetzler, A. Espay, P. Martinez-Martin, G. Stebbins, A. Sánchez-Ferro (Móstoles, Madrid, Spain)

  • Towards a method for accurate detection of diphasic dyskinesia

    K. Tsamis, G. Rigas, N. Tachos, D. Kakalou, N. Kostikis, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)

  • Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease

    P. Millar Vernetti, J.A Palma, L. Norcliffe-Kaufmann, M. Pérez, A. Fanciulli, F. Krismer, W. Singer, P. Low, M.T Pellecchia, H.J Kim, C. Shibao, A. Peltier, I. Biaggioni, M.J Martí, C. Terroba-Chambi, M. Merello, D. Goldstein, R. Freeman, C. Gibbons, S. Vernino, G. Wenning, H. Kaufmann (New York, NY, USA)

  • Tractography of the corticospinal tract in Parkinson’s disease. How does diffusion values vary along tract segments?

    R. Guimarães, L. Ramalho, B. Campos, L. Piovesana, P. Azevedo, F. Cendes (Campinas, Brazil)

  • Trajectories of pain in newly diagnosed Parkinson’s disease

    J. Naisby, R. Lawson, B. Galna, L. Alcock, D. Burn, L. Rochester, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

  • Transcranial brain sonography can distinguish drug induced parkinsonism from idiopathic Parkinson’s disease in Korean?

    M. Park, H. Park (Daegu, Republic of Korea)

  • Transcranial direct current stimulation over the supplementary motor area in Tourette syndrome: Preliminary findings of a randomized controlled trial

    D. Martino, E. Nosratmishekarlou, Y. Jasaui, A. Medina, C. Vicario, M. Nitsche, L. Gan, T. Pringsheim (Calgary, AB, Canada)

  • Transcranial sonography in HIV infection: Does it reflect infectious and neurological symptoms?

    A. Alonso-Canovas, J. Martinez Poles, M.J Pérez Elías, J.L Casado Osorio, A.M Moreno Zamora, C. Quereda Rodríguez-Navarro, E. Navas Elorza, F. Dronda Núñez, M.J Vivancos Gallego, S. Moreno Guillen, J. Masjuan, J.C Martinez Castrillo, I. Corral (Madrid, Spain)

  • Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)

    J.R Menezes, R.B Carra, G.A Nunes, J.S Simões, M.J Teixeira, K.P Duarte, D.C Andrade, E.R Barbosa, M.A Marcolin, R.G Cury (São Paulo, Brazil)

  • Transcutaneous spinal cord current stimulation modulate Reactive Oxygen Species (ROS) in multiple sclerosis patients

    S. Mrakic-Sposta, R. Ferrucci, S. Floro, F. Ruggiero, M. Vergari, S. Versace, S. Santoni, A. Vezzoli, M. Massei, M. Deriz, S. Marceglia, S. Barbieri, A. Priori (Milan, Italy)

  • Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies

    A. Valles, M. Evers, A. Stam, M. Sogorb-Gonzales, C. Brouwers, C. Vendrell, S. Acar-Broekmans, V. Fodale, A. Bresciani, R. Nieuwland, Z. Ellederova, J. Motlik, M. de Haan, B. Leavitt, S. van Deventer, P. Konstantinova (Amsterdam, Netherlands)

  • Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease

    M. Javidnia, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

  • Treatment of hemichorea-hemiballism with valbenazine

    J. Leegwater-Kim (BURLINGTON, MA, USA)

  • Treatment of medically refractory orthostatic tremor: deep brain stimulation of bilateral thalamic ventral intermediate nucleus with sustained symptomatic improvement

    D. Sugar, M. Zorn, C. Aquino, J. Rolston, P. Moretti (Salt Lake City, UT, USA)

  • Treatment of Medication-Refectory Holmes Tremor by Simultaneous Thalamic Ventral Intermediate (VIM) Nucleus and Subthalamic Nucleus (STN) Deep Brain Stimulation-A Case Report

    M. Anjum, C. Kalhorn, Y. Torres-Yaghi, A. Carwin, F. Pagan (Washington, DC, USA)

  • Treatment of Neurogenic Orthostatic Hypotension (nOH) in Multiple System Atrophy (MSA) with a wearable Pneumatic Compression Garment utilising Soft Robotics

    N. Sawal, H. Singh, A. Beri (Chandigarh, India)

  • Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity

    J. Lester, G. Alvarez-Resendiz, E. Klériga, F. Videgaray, G. Zambito (Huixquilucan, Mexico)

  • Tremor-dominant cervical dystonia and the cerebellum: lessons from saccade adaptation

    A. Mahajan, P. Gupta, J. Jacobs, L. Marsili, A. Sturchio, H. Jinnah, A. Espay, A. Shaikh (Cincinnati, OH, USA)

  • Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with Parkinson’s Disease

    S. Jimsheleishvili, D. Di Luca, M. Feldman, J. Margolesky, D. Shpiner, C. Singer, C. Luca (Miami, FL, USA)

  • Triggers and Alleviating Factors for Fatigue in Parkinson’s Disease

    I. Lin, B. Edison, S. Mantri, M. Daeschler, K. Kopil, C. Marras, L. Chahine (Pittsburgh, PA, USA)

  • Twiddler’s Syndrome in Deep Brain Stimulation

    V. Shivkumar, J. Adams (Huntington, WV, USA)

  • Two cases of Ataxia Telangiectasia Like Disorder: phenotypic spectrum associated with MRE11 gene

    I. Raslan, P. Matos, V. Ciarlarello, C. Jaques, J. Pedroso, O. Barsottini (São Paulo, Brazil)

  • Type 2 diabetes mellitus may worsen severity of motor symptoms in people with Parkinson’s disease

    A. Ben-Joseph, T. Haque, D. Gallagher, C. Budu, R. Chaudhuri, C. Simonet, A. Noyce (London, United Kingdom)

  • Type-3 Metabotropic Glutamate Receptors and Parkinson’s Disease: Preclinical Studies and Human Genetics

    M. Alborghetti, L. Di Menna, A. Traficante, V. Bruno, J. Monn, F. Nicoletti, F.E Pontieri, E. Bianchini, G. Spalletta, M. Borro, M. Simmaco, G. Battaglia (Rome, Italy)

  • Types of Pain in Parkinson`s Disease Patients

    I. Petrov (Skopje, The former Yugoslav Republic of Macedonia)

Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley